Verastem, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $7.41
- 52-Week Range
- $3.43 – $10.82
- Market Cap
- $865.72M
- P/E (TTM)
- —
- EPS (TTM)
- -1.84
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 64.21
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -59.75%
- Gross Margin
- 87.23%
- Operating Margin
- -193.73%
- Profit Margin
- -178.38%
- Current Ratio
- 1.93
- Debt/Equity
- 12.73
- Total Debt
- $128.56M
- Free Cash Flow
- $-92.65M
- Revenue Growth
- 113.60%
- Earnings Growth
- —
- Enterprise Value
- $821.48M
Market Snapshot
About
Verastem, Inc. is a biopharmaceutical company committed to developing and commercializing medicines to improve the lives of patients diagnosed with cancer. The company focuses on treatments targeting critical signaling pathways in cancer cells, with a particular emphasis on therapies for RAS pathway-driven cancers and difficult-to-treat malignancies. Verastem employs precision medicine approaches to identify patients most likely to benefit from its targeted therapies.